Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02466243 · ClinicalTrials.gov registry record · Phase 2
Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis
A Phase 2 study, sponsored by Corbus Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02466243: Clinical Trial Phase 2 study, sponsored by Corbus Pharmaceuticals.
NCT02466243 is a Phase 2 study that was terminated before completion, run by Corbus Pharmaceuticals. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02466243, a Phase 2 study, was terminated before completion, sponsored by Corbus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3 months treatment with hydroxychloroquine.
Primary Outcome
The CDASI is a validated outcome measure that systematically quantifies cutaneous DM disease activity, In the CDASI, DM skin disease activity is scored from 0 to 100 based on the physician's evaluation of erythema, scale, and erosion or ulceration at 15 anatomic locations as well as alopecia, Gottron's sign or papules on the hands, and periungual changes. A 5-point or greater decrease in the CDASI activity score indicates clinically relevant improvement based on statistical analysis using a rece
Interventions
- DRUG Placebo
- DRUG JBT-101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-06 |
| Est. Completion | 2021-01-29 |
| Phase | Phase 2 |
Why NCT02466243 stopped before completion
NCT02466243 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02466243 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02466243 about?
NCT02466243 is a clinical study titled "Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis". The purpose of this study is to evaluate the safety, tolerability and efficacy of JBT-101 in adult subjects with skin-predominant, dermatomyositis (DM) that is refractory to at least 3 months treatment with hydroxychloroquine.
What is the current status of trial NCT02466243?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2015-06. Estimated completion is 2021-01-29.
What interventions are being tested in trial NCT02466243?
The interventions under investigation include: Placebo (DRUG), JBT-101 (DRUG).
Who is sponsoring clinical trial NCT02466243?
This trial is sponsored by Corbus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02466243's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia